Skip to main content
TipRanks
Go Ultimate75% OFF

Anthony Maida Insider Profile

4 Followers

Anthony Maida, Chief Clin. Ops. Officer, Director at Oncotelic Therapeutics, holds 1.14M shares in Oncotelic Therapeutics (Ticker: OTLC), holds 29.61K shares in Spectrum Pharmaceuticals (Ticker: SPPI), holds ― shares in 9 Meters Biopharma (Ticker: NMTRQ).

Anthony Maida's Trading History

OTLC
Oncotelic Therapeutics
Jul 16, 2021Chief Clin. Ops. Officer, DirectorUninformative Buy―$14.79K
SPPI
Spectrum Pharmaceuticals
Apr 12, 2019―Uninformative Sell114.57K$30.50K
ONCSQ
OncoSec Medical
Mar 20, 2014DirectorInformative Buy18.46K―
RNGE
Range Impact
―Director――
NMTRQ
9 Meters Biopharma
―Director――

You May Also Like

Anthony Maida insider profile FAQ

What is the percentage of profitable transactions made by Anthony Maida?
The percentage of profitable transactions made by Anthony Maida is 50%.
What is the average return per transaction made by Anthony Maida?
The average return per transaction made by Anthony Maida is -19.80%.
What stocks does Anthony Maida hold?
Anthony Maida holds: OTLC, SPPI, NMTRQ, RNGE, ONCSQ stocks.
What was Anthony Maida's most profitable transaction?
Anthony Maida’s most profitable transaction was an Informative Sell of SPPI stock on December 16, 2014. The return on the trade was 15.90%.
What is Anthony Maida's role in Oncotelic Therapeutics?
Anthony Maida's role in Oncotelic Therapeutics is Chief Clin. Ops. Officer, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.